ADVANCED ESOPHAGEAL ADENOCARCINOMA
Clinical trials for ADVANCED ESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED ESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED ESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise in stomach cancer trial
Disease control Recruiting nowThis study tests whether adding the drug ivonescimab to standard chemotherapy helps shrink tumors in people with advanced stomach or esophageal cancer. About 88 participants will receive treatment every two weeks. The main goal is to see if more patients respond to the combinatio…
Matched conditions: ADVANCED ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated May 26, 2026 07:35 UTC
-
Could a stronger chemo cocktail extend life for stomach cancer patients?
Disease control Recruiting nowThis study compares two chemotherapy combinations for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery or has spread. About 382 participants will receive either the standard FOLFOX chemo (with or without the immunothe…
Matched conditions: ADVANCED ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 26, 2026 07:25 UTC
-
New drug combo shows promise in advanced stomach cancer trial
Disease control Recruiting nowThis study is for people with advanced stomach or esophageal cancer that has spread. It tests whether adding the immunotherapy drug nivolumab to the usual two-drug treatment (paclitaxel and ramucirumab) helps control the cancer longer. About 224 participants will be randomly assi…
Matched conditions: ADVANCED ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:24 UTC
-
New pill targets common cancer driver in advanced tumors
Disease control Recruiting nowThis early-phase study tests a new experimental drug called BGB-53038 in people with advanced or metastatic solid tumors that have a specific genetic change (KRAS mutation or amplification). The drug is a pan-KRAS inhibitor, meaning it aims to block many forms of the faulty KRAS …
Matched conditions: ADVANCED ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated May 13, 2026 16:02 UTC